Paclitaxel Injection

Category: Antineoplastic / Chemotherapy drug (Taxane class)
Form: Injectable solution for intravenous (IV) use

Uses:

• Treatment of various cancers, including:

  • Breast cancer

  • Ovarian cancer

  • Non-small cell lung cancer (NSCLC)

  • Kaposi’s sarcoma

• Often used in combination with other chemotherapy agents for improved efficacy.

Mechanism of Action:

• Paclitaxel stabilizes microtubules in cells.

• Prevents the normal breakdown of microtubules during cell division.

• This arrests the cell cycle at the mitotic phase, preventing cancer cells from dividing and leading to apoptosis (cell death).

• Targets rapidly dividing cells, which is characteristic of tumors.

Administration:

• Administered intravenously over a period of several hours, depending on the protocol.

• Premedication with antihistamines, corticosteroids, and H2 blockers is recommended to reduce the risk of hypersensitivity reactions.

• Dosage is calculated based on body surface area, cancer type, and treatment regimen.

Side Effects:

• Hematologic: neutropenia, thrombocytopenia, anemia.

• Neurological: peripheral neuropathy, tingling, numbness.

• Gastrointestinal: nausea, vomiting, diarrhea, mucositis.

• Other: hair loss, fatigue, hypersensitivity reactions, joint and muscle pain.

• Rarely: cardiac effects in susceptible patients.

Precautions:

• Monitor blood counts closely due to risk of myelosuppression.

• Use caution in patients with pre-existing neuropathy or liver dysfunction.

• Patients should be monitored for hypersensitivity reactions during infusion.

Summary:
Paclitaxel Injection is a chemotherapy drug from the taxane class that inhibits cancer cell division by stabilizing microtubules. It is used to treat multiple cancers, including breast, ovarian, and lung cancer. Administration is intravenous with premedication to prevent allergic reactions. Side effects include blood cell suppression, neuropathy, gastrointestinal upset, and hair loss.